SRTS

Sensus Healthcare, Inc. (SRTS) - Q3 2025 10-Q Summary

Business Context and Reporting Period

Sensus Healthcare, Inc. is a medical device company manufacturing radiation therapy devices (SRT-100 series) for oncological and non-oncological skin conditions. The company operates globally with a primary focus on the U.S. dermatology market. This report covers the quarterly period ended September 30, 2025.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased 21.6% year-over-year for both the quarter and the nine-month period. This was driven by a significant drop in unit sales (16 units in Q3 2025 vs. 27 in Q3 2024) and reduced sales to a single large U.S. customer.
• Margin Compression: Gross margin fell from 59.1% to 39.1% in Q3. This was caused by lower sales volume combined with higher servicing costs and upfront costs for a new placement program (installation and training) recognized before related revenue.
• Expense Increases:
  • R&D: Increased 100% in Q3 (to $1.8M) and 118.5% YTD (to $5.9M) due to lobbying costs for billing code reimbursement, increased headcount, and next-generation product development.
  • Selling & Marketing: Increased 15.4% in Q3 due to commissions and headcount growth.
  • G&A: Increased 18.8% in Q3 due to professional fees and compensation.
• Balance Sheet: Accounts receivable decreased by $10.4 million to $9.3 million, reflecting lower sales and the payment terms of the primary customer. Inventory increased by $2.9 million to $13.0 million in anticipation of future sales.

Outlook, Risks, and Contingencies

• Debt Covenant Waiver: The company failed to meet the minimum profitability covenant ($1.0M trailing 12-month) under its $15M Comerica Bank credit facility as of June 30, 2025. Comerica issued a waiver on September 26, 2025, agreeing to forebear from exercising rights provided the company complies with other terms. No borrowings are currently outstanding.
• Customer Concentration: One U.S. customer accounted for 59% of Q3 revenue and 86% of accounts receivable. The company faces significant risk if this customer's demand or payment terms change.
• Legal Proceedings: The Department of Justice is investigating billing practices of a physician using Sensus devices. The company disputes any wrongdoing, noting it does not submit claims or provide billing advice, but cannot estimate potential costs.
• Tax Position: The effective tax rate for Q3 was 60.9% (vs. 31.5% prior year) due to a high proportion of tax credits (R&D and others) relative to pre-tax income. Management expects the full-year 2025 rate to differ materially from the statutory 21% rate.
• Liquidity: Management believes cash, cash equivalents, and borrowing capacity are sufficient to meet requirements for the next 12 months.

Investor Verification Checklist

• Customer Concentration Risk: Verify the stability of the relationship with the single customer representing 59% of Q3 revenue and 86% of receivables.
• Debt Covenant Compliance: Monitor the company's ability to meet the profitability covenant ($1M trailing 12-month) to avoid future defaults on the Comerica credit facility.
• DOJ Investigation Status: Track updates on the Department of Justice investigation regarding Medicare billing codes to assess potential liability.
• Margin Recovery: Assess whether the new placement program will generate sufficient recurring revenue to offset the upfront costs currently depressing gross margins.
• R&D Spend Efficiency: Evaluate the return on the significant increase in R&D spending, particularly regarding lobbying efforts for billing code reimbursement.